TCGA-AR-A24Z-01A-11R-A169-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 100
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- PROTEIN_SECRETION+0.470
- G2M_CHECKPOINT+0.450
- E2F_TARGETS+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.330
- MITOTIC_SPINDLE+0.320
- MTORC1_SIGNALING+0.230
- ANDROGEN_RESPONSE+0.190
- INTERFERON_GAMMA_RESPONSE+0.180
- ESTROGEN_RESPONSE_EARLY+0.170
Top 10 suppressed
- MYOGENESIS-0.440
- WNT_BETA_CATENIN_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.380
- CHOLESTEROL_HOMEOSTASIS-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- ANGIOGENESIS-0.340
- P53_PATHWAY-0.330
- APICAL_JUNCTION-0.320
- COAGULATION-0.310
- TNFA_SIGNALING_VIA_NFKB-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A22H-01A-11R-A157-07 | — | B | 0.846 |
| 2 | TCGA-AR-A24R-01A-11R-A169-07 | — | B | 0.828 |
| 3 | TCGA-BH-A0DD-01A-31R-A12P-07 | — | B | 0.826 |
| 4 | 65567450-e04a-4251-9939-8d2545077236 | — | — | 0.814 |
| 5 | R135 | — | — | 0.814 |
| 6 | TCGA-AR-A0U3-01A-11R-A109-07 | — | B | 0.804 |
| 7 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.796 |
| 8 | SRR25617939 | — | B | 0.793 |
| 9 | MNG274 | — | — | 0.785 |
| 10 | R137 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |